Maxipime Side Effects
Generic name: cefepime
Note: This document contains side effect information about cefepime. Some of the dosage forms listed on this page may not apply to the brand name Maxipime.
Some side effects of Maxipime may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to cefepime: injection powder for solution
Along with its needed effects, cefepime (the active ingredient contained in Maxipime) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cefepime:More common
- Abdominal or stomach cramps
- back, leg, or stomach pains
- bleeding gums, nosebleeds
- dark urine
- difficulty with breathing
- fever, chills
- general body swelling
- irregular heartbeats
- loss of appetite
- mood or mental changes
- muscle cramps in the hands, arms, feet, legs, or face
- nausea or vomiting
- numbness and tingling around the mouth, fingertips, or feet
- yellowing of the eyes or skin
- Bluish color
- pain, tenderness
- swelling of the foot or leg
- inflammation or swelling
- watery or bloody diarrhea
- blistering, peeling, or loosening of the skin
- bloody or cloudy urine
- bloody, black, or tarry stools
- blurred vision
- change in consciousness
- chest pain
- cough or hoarseness
- difficult or painful urination
- difficulty with swallowing
- fast heartbeat
- general feeling of tiredness or weakness
- itching, hives
- muscle twitching or jerking
- pinpoint red spots on the skin
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- red skin lesions, often with a purple center
- rhythmic movement of the muscles
- seeing, hearing, or feeling things that are not there
- severe sleepiness
- stiff neck
- sudden decrease in the amount of urine
- swollen or painful glands
- unpleasant breath odor
- unusual bleeding or bruising
- vomiting of blood
Some side effects of cefepime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- Red streaks on the skin
- swelling, tenderness, or pain at the injection site
- Itching of the vagina or genital area
- pain during sexual intercourse
- redness of the skin
- sore mouth or tongue
- thick, white vaginal discharge with no odor or with a mild odor
- white patches in the mouth, tongue, or throat
For Healthcare Professionals
Applies to cefepime: injectable powder for injection, injectable solution
Cefepime (the active ingredient contained in Maxipime) is generally well tolerated. It has been reported that 1.5% of patients discontinued medication due to adverse events.
If diarrhea occurs which is unresponsive to discontinuation of cefepime (the active ingredient contained in Maxipime) and/or standard therapy, pseudomembranous colitis should be considered.
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including diarrhea (3%), nausea (2%), and vomiting (1%).
Uncommon (0.1% to 1%): Colitis (including pseudomembranous colitis), diarrhea, nausea, vomiting, oral moniliasis
Frequency not reported: Abdominal pain, anorexia, stomatitis, Clostridium difficile associated diarrhea
Local reactions (3%), including phlebitis (1.3%) and pain and/or inflammation (0.6%), have been reported irrespective to cefepime (the active ingredient contained in Maxipime) in patients who received intravenous infusion.
Common (1% to 10%): Local reactions (3%)
Uncommon (0.1% to 1%): Phlebitis (1.3%), pain and/or inflammation (0.6%)
Frequency not reported: Infusion site reaction
Uncommon (0.1% to 1%): Headache
Frequency not reported: Somnolence
Postmarketing reports: Neurotoxicity, encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, coma), myoclonus, seizures, nonconvulsive status epilepticus
Encephalopathy, myoclonus, seizures, and nonconvulsive status epilepticus have been reported. Although most cases occurred in patients with renal impairment who received higher than recommended doses of cefepime, some cases of neurotoxicity occurred in patients receiving an appropriate dosage for their degree of renal impairment. In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis.
Case reports of seizure activity, with and without convulsions, associated with cefepime have been published in the medical literature. In the vast majority of cases, the patient involved had a clinically significant degree of renal dysfunction. In each case, seizure activity abated upon the discontinuation of cefepime.
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including headache (1%).
A 66-year-old female developed acute renal failure, altered level of consciousness (Glasgow Coma Scale 6), and nonconvulsive status epilepticus after 10 days of cefepime 2 g every 8 hours. Symptoms resolved and she completely recovered 72 hours after discontinuation of cefepime.
Common (1% to 10%): Rash (1.1%)
Uncommon (0.1% to 1%): Urticaria, pruritus, erythema
Rare (less than 0.1%): Red man syndrome (at least 1 case)
Frequency not reported: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis
Higher doses (2 grams every 8 hours) have been associated with a higher incidence of side effects, including rash (4%) and pruritus (1%).
Cephalosporin class antibiotics have been associated with Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.
Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, and pancytopenia.
Very common (10% or more): Positive Coombs' test (without hemolysis; 16.2%)
Common (1% to 10%): Increased eosinophils (1.7%), abnormal PTT (1.6%), abnormal PT (1.4%)
Uncommon (0.1% to 1%): Decreased hematocrit, decreased neutrophils, decreased platelets, decreased white blood cells, anemia
Frequency not reported: Epistaxis, aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, pancytopenia
Anaphylactic reactions are rare, but may occur, especially in patients with a history of penicillin allergy.
Cephalosporin class antibiotics have been associated with allergic reactions.
Frequency not reported: Acute hypersensitivity myocarditis, allergic reactions
Postmarketing reports: Anaphylaxis (including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia)
Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.
Common (1% to 10%): Increased ALT (2.8%), increased AST (2.4%)
Uncommon (0.1% to 1%): Increased alkaline phosphatase, increased total bilirubin
Frequency not reported: Hepatic dysfunction including cholestasis
Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported.
Common (1% to 10%): Decreased phosphorus (2.8%)
Uncommon (0.1% to 1%): Decreased calcium, increased calcium, increased phosphorus, increased potassium
Frequency not reported: Hypokalemia, hypomagnesemia
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including fever (1%).
Uncommon (0.1% to 1%): Fever
Renal failure, mostly in patients with renal impairment who received higher than recommended doses of cefepime (the active ingredient contained in Maxipime) has been reported.
Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.
Uncommon (0.1% to 1%): Increased BUN, increased creatinine
Frequency not reported: Renal failure, renal dysfunction, toxic nephropathy
Uncommon (0.1% to 1%): Vaginitis
Frequency not reported: Cough, dyspnea
Frequency not reported: Tachycardia
More Maxipime resources
- Maxipime Prescribing Information (FDA)
- Maxipime MedFacts Consumer Leaflet (Wolters Kluwer)
- Maxipime injection Concise Consumer Information (Cerner Multum)
- Maxipime Monograph (AHFS DI)
- Maxipime Advanced Consumer (Micromedex) - Includes Dosage Information
- Cefepime Professional Patient Advice (Wolters Kluwer)
- Cefepime Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.